Activity Details

0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hours for nurses
Released: March 6, 2018
Expires: March 5, 2019
15 minutes to complete

Provided By

Target Audience

This activity is intended for medical oncologists, surgical oncologists, radiation oncologists, orthopedic oncologists, pathologists, researchers, advanced practitioners, nurses, and other healthcare professionals who treat soft-tissue sarcomas.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Integrate dosing and administration recommendations for treatment with doxorubicin plus olaratumab
  • Use appropriate therapies for the treatment of soft-tissue sarcomas according to guideline recommendations
  • Identify appropriate treatments for uterine sarcoma
  • Recognize and manage adverse events in patients being treated for soft-tissue sarcomas
  • Assess advances in molecular testing in determining treatment approach
  • Evaluate emerging data for the use of immunotherapy in the treatment of soft-tissue sarcomas

Activity Description

Soft-tissue sarcomas (STS) comprise a heterogeneous group of rare diseases of mesenchymal origin. Its rarity (1% of adult malignancies) and diverse presentation (180+ classified subtypes) make STS a challenge to diagnose and treat. The standard of care involves a multimodal approach of radiation therapy, surgery, and chemotherapy; however, the 5-year survival rate for advanced/metastatic STS has remained approximately 16% for many years. Fortunately, there are multiple newly approved and emerging agents in late-stage clinical trials that may revolutionize the treatment of STS.

Because STS treatment is rapidly evolving, clinicians may not be up to date regarding the latest advances in the treatment of this disease, including available, newer, and emerging treatment options, making it challenging to provide state-of-the-art care to their patients.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. The topics outlined below feature a summary of the questions that were asked during a recent grand rounds series on sarcoma. This activity will review:

  • Dosing and administration of olaratumab
  • Treatments for uterine sarcoma
  • Adverse events and management
  • Choice of treatment/therapy
  • Optimal surveillance schedule for localized disease
  • The role of adjuvant chemotherapy
  • Molecular testing
  • The use of immunotherapy

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the treatment of sarcoma so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices for their patients.


Richard F. Riedel, MD
Associate Professor with Tenure
Division of Medical Oncology
Associate Director, Clinical & Translational Research Duke Sarcoma Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Conflict of Interest Policy/Disclosure Statement

The faculty, Richard F. Riedel, MD, reported a financial interest/relationship or affiliation in the form of Consultant/Advisory boards, Eisai Inc., EMD Serono, Ignyta, Janssen Biotech, Inc., Lilly USA, Loxo Oncology; Contracted research, Aadi Bioscience, Inc., AROG Pharmaceuticals, Inc., Bayer Pharmaceuticals Corporation, Eisai Inc., Ignyta, Immune Design, Karyopharm Therapeutics, Lilly USA, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Plexxikon, TRACON Pharmaceuticals, Inc.; Ownership, Biotech Prosthetics & Orthotics of Durham (Spouse), Limbguard, LLC (Spouse).

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Continuing Education Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other related information.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.